Interim Report Q4 - January - December, 2024 Redsense Medical AB (publ.)
OCTOBER - DECEMBER 2024
- Net sales amounted to kSEK 12,687 (8,025).
- Operating profit, EBIT amounted to kSEK 5,525 (-927).
- Result after tax amounted to kSEK 5,629 (-950).
- Earnings per share were SEK 0,34 (-0,07).
- Other operating income/loss kSEK 1,771 (-961).
SIGNIFICANT EVENTS DURING THE PERIOD
- On October 16, Redsense announced that the nomination committee for the 2025 Annual General Meeting in Redsense Medical AB was appointed.
- On October 24, Redsense announced that it will not renew its agreement with OTC Markets Group, resulting in the cessation of trading on the OTCQX platform in the USA.
SIGNIFICANT EVENTS AFTER THE PERIOD
- On January 21, Redsense announced the completion of the Clamp usability testing phase.
- On January 31, Redsense announced the passing of Board Member Malin Almgren.
- On February 10, Redsense announced the company reinforced the team with a new CFO and part-time support functions.
COMMENT FROM THE CEO
A strong finish to 2024 and a promising start to 2025
As we close out 2024, I am pleased to share that Redsense Medical has delivered the strongest ever quarter to date with 12,7 mSEK in sales. Our sales results in Q4 benefitted from the partial Q3 order that was delivered in the first week of October. The December review with our U.S. distribution partners resulted in another round of replenishment orders, further reinforcing the stability and predictability of our sales pipeline. This increase in sales leads to the first full year positive result in Redsense history.
With the improvements we made in the last quarter of the year-streamlining operations, strengthening partnerships, and enhancing internal processes-we are well positioned for continued progress in 2025. The net sales for Q1 2025 to date exceed 3M SEK, with the quarter review with our US distribution partners planned in March.
Progress on U.S. reimbursement efforts
Our work toward securing U.S. reimbursement remains a key strategic priority. While legislative progress has been slower than anticipated, we are actively pursuing alternative avenues, including working with local intermediaries and advancing HCPCS coding efforts. Our HCPCS application is currently in review, which is ahead of the initial timeline. Preliminary findings from the reviewing body are expected by April/May 2025.
Launching the Redsense Clamp
One of our key milestones for early 2025 is the commercial launch of the Redsense Clamp. The usability testing phase was completed in January 2025 and with the summative evaluation report submitted for regulatory review, we remain on track for initial sales by the end of Q1 2025 through our distribution partners in the UK and Canada. We are convinced this innovation will attract new customers and further strengthen our position in the market.
Investing in our team and operations
A major focus as we enter 2025 is continuing to build a strong, efficient organization. We are working to refine internal processes and align our team to further enhance efficiency, collaboration, and execution across the company. A well-structured team and optimized processes will be crucial in achieving our strategic objectives in the coming year.
Looking ahead
With a successful Q4 behind us, we are entering 2025 with confidence. The groundwork we have laid so far positions us well for a year of growth and expansion. I would like to extend my gratitude to all shareholders, partners, customers, as well as the Redsense team, for their dedication and trust. Together, we are driving Redsense Medical toward a bright future, and I look forward to the opportunities that lie ahead in 2025.
Sebastien Bollue
CEO of Redsense Medical
This information is information that Redsense Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication, through the agency of the contact person specified above, on February 26, 2025, at 08:30 CET.